Compare Enovix Corporation (ENVX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Summit Therapeutics Inc — how do they compare? Enovix Corporation trades at $2.46 (market cap $549.72M), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 24.9× Enovix Corporation's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Summit Therapeutics Inc for 16 Days on average.
| ENVX | SMMT | |
|---|---|---|
Market Cap | $549.72M | $13.71B |
Volume | 6,635,687 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $13.19 | $26.38 |
52-Week Low | $2.50 | $12.43 |
Typical Hold Time | 11 Days | 16 Days |
Enterprise Value | $611.42M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, with technical indicators signaling a bearish trend. The company reported a net loss of $156.74 million in 2025, with revenue of $31.82 million, and continues to burn cash, though it has beaten EPS estimates in recent quarters. Recent news includes CEO transition and expansion of battery manufacturing capacity.
Despite consistent EPS beats, ENVX faces significant financial challenges with negative margins and cash burn. Analyst consensus is bullish with a $10.75 price target, but high execution risk and leadership changes pose threats to near-term stability and long-term growth prospects.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
